Aescin in Horse Chestnut
Phase 1Small molecule
Aescin in Horse Chestnut is one of 32 small molecule programs targeting Hemorrhoid. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Hemorrhoid
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Cardizem
BBausch Health Americas, Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Nitrostat
VViatris Specialty LLC
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Kenalog
BBassett Healthcare
Approved
Celestone
SSchering-Plough
Approved
Flagyl
DDePuy Orthopaedics
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hemorrhoid2 trials
The Efficacy of Aescin in Combination With Micronized Purified Flavonoid Fraction (MPFF) in the Control of Bleeding and Prevent Recurrence of Acute Internal Hemorrhoids, A Randomized Controlled Trial, A Pilot Study
Enrolling by invitation·—·Phase 1·NCT06748014·120 enrolled
The Efficacy of Aescin in Combination With MPFF in the Early Control of Bleeding From Acute Internal Hemorrhoids, A Randomized Controlled Trial
Not yet recruiting·—·N/A·NCT06363513·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aescin in Horse Chestnut. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CChiang Mai University